The company’s decision to combine these components marks a departure from single-ingredient trends, aiming to streamline advanced treatment protocols. Each ingredient serves a specific clinical function: Botulinum Peptide targets skin refinement, while GHK-Cu and Succinic Acid focus on conditioning and antioxidant support. PDRN and Exosomes round out the formula to address deeper tissue regeneration and recovery needs.
MAYPHARM Expands Aesthetic Portfolio with HYALMASS AQUATOX
Seoul-based MAYPHARM is targeting the shifting demands of the global aesthetic market with the upcoming release of HYALMASS AQUATOX. The new formulation consolidates five high-interest active ingredients—PDRN, Exosomes, Botulinum Peptide, GHK-Cu, and Succinic Acid—into a single product designed for multifunctional skin rejuvenation and recovery.
This launch builds on the international momentum of the existing HYALMASS AQUA EXOSOME line. However, as the market sees a rise in products mimicking popular ingredient profiles and visual branding, MAYPHARM is urging distributors and aesthetic professionals to prioritize supply chain transparency. The company stresses that verifying authorized distribution channels and original packaging remains critical for ensuring product authenticity and patient safety as they scale their presence in the global sector.
Comments (0)
No comments yet. Be the first!